Exagen Inc. announced the appointment of Debra Jeske Zack, M.D., Ph.D., as Chief Medical Officer (CMO), and Anja Kammesheidt, Ph.D., as Chief Scientific Officer (CSO). The addition of Drs. Zack and Kammesheidt to the Exagen team will strengthen the company as it continues to focus on clinical research and development initiatives to serve the needs of healthcare providers and their patients. Prior to joining Exagen, Dr. Zack served as Vice President, Clinical Development at Xencor Inc.; Executive Director, Medical Scientific Leader, Biotherapeutics Development Unit at Novartis; and various positions in basic research, clinical development and medical affairs at Amgen. Dr. Zack replaces Dr. Arthur Weinstein, who is leaving the CMO position to focus his attentions as the chair of the Scientific Advisory Board. Prior to joining Exagen, Dr. Kammesheidt served as Chief Scientific Officer at Ambry Genetics and Pathway Genomics, and also held R&D positions at Agendia Inc. and Purdue Pharma. Dr. Kammesheidt replaces Dr. Thierry Dervieux, who has been serving as a consultant to Exagen since his resignation from the company in Fourth Quarter 2019 to pursue other opportunities.